INNATE PHARMA SA (IPHA): Price and Financial Metrics


INNATE PHARMA SA (IPHA): $3.45

-0.01 (-0.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IPHA Stock Summary

  • With a one year PEG ratio of 0.47, INNATE PHARMA SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
  • Of note is the ratio of INNATE PHARMA SA's sales and general administrative expense to its total operating expenses; merely 11.9% of US stocks have a lower such ratio.
  • As for revenue growth, note that IPHA's revenue has grown -35.28% over the past 12 months; that beats the revenue growth of just 5.63% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to INNATE PHARMA SA, a group of peers worth examining would be PRQR, GERN, MEIP, VTGN, and OGEN.
  • IPHA's SEC filings can be seen here. And to visit INNATE PHARMA SA's official web site, go to www.innate-pharma.com.

IPHA Stock Price Chart Interactive Chart >

Price chart for IPHA

IPHA Price/Volume Stats

Current price $3.45 52-week high $4.10
Prev. close $3.46 52-week low $1.90
Day low $3.24 Volume 16,400
Day high $3.49 Avg. volume 21,178
50-day MA $2.81 Dividend yield N/A
200-day MA $2.68 Market Cap 276.73M

INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about INNATE PHARMA SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Innate, Sanofi licensing deal gets US antitrust clearance

  • Innate Pharma (NASDAQ:IPHA) and Sanofi (NASDAQ:SNY) said the expansion of their collaboration on natural killer (NK) cell engagers under a licensing agreement became effective as the waiting period under the Hart-Scott-Rodino (...

    Seeking Alpha | January 25, 2023

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

MARSEILLE, France, January 25, 2023--Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers

Yahoo | January 25, 2023

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

MARSEILLE, France, January 16, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.

Yahoo | January 16, 2023

How did Innate Pharma S.A. (IPHA) fare last session?

Innate Pharma S.A. (NASDAQ:IPHA) closed Tuesday at $3.14 per share, up from $2.81 a day earlier. While Innate Pharma S.A. has overperformed by 11.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IPHA fell by -38.19%, with highs and lows ranging from $5.34 to $1.90, whereas […]

US Post News | December 28, 2022

Investing in Innate Pharma S.A. (IPHA) might be a great opportunity, but the stock is a bit overvalued

The share price of Innate Pharma S.A. (NASDAQ:IPHA) rose to $2.65 per share on Monday from $1.90. While Innate Pharma S.A. has overperformed by 39.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IPHA fell by -49.81%, with highs and lows ranging from $5.38 to $1.90, […]

US Post News | December 20, 2022

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo -3.90%
3-mo 60.47%
6-mo 22.78%
1-year -3.90%
3-year -51.63%
5-year N/A
YTD -7.51%
2022 -18.20%
2021 11.49%
2020 -36.49%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7325 seconds.